Framingham, MA, United States of America

Jozsef Karman



Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 21(Granted Patents)


Location History:

  • Bridgewater, NJ (US) (2017)
  • Framingham, MA (US) (2021 - 2024)

Company Filing History:


Years Active: 2017-2024

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Jozsef Karman: Innovator in T-cell Activation Inhibitors

Introduction

Jozsef Karman is a notable inventor based in Framingham, MA (US). He has made significant contributions to the field of immunology, particularly in the development of inhibitors for T-cell activation. With a total of three patents to his name, Karman's work is paving the way for advancements in therapeutic interventions.

Latest Patents

Among his latest patents, Karman has developed a bispecific biologic that comprises a ligand specific for CTLA-4 and a ligand specific for a pMHC complex. This innovative approach aims to enhance the efficacy of T-cell modulation, which is crucial for various immunological therapies. His work in this area demonstrates a commitment to improving treatment options for patients with immune-related conditions.

Career Highlights

Karman is currently associated with Genzyme Corporation, a leading biotechnology company known for its focus on rare diseases and innovative therapies. His role at Genzyme allows him to collaborate with other experts in the field and contribute to groundbreaking research and development.

Collaborations

Some of his notable coworkers include Yunxiang Zhu and Canwen Jiang. Their collaborative efforts in research have further strengthened the advancements in the field of immunology.

Conclusion

Jozsef Karman's contributions to the field of T-cell activation inhibitors highlight his innovative spirit and dedication to advancing medical science. His work continues to inspire future research and development in immunotherapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…